medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 1

<< Back Next >>

Ann Hepatol 2012; 11 (1)

Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?

Florentino G, Cotrim HP, Florentino A, Padilha C, Medeiros-Neto M, Bragagnoli G, Schwingel P

Language: English
References: 12
Page: 147-149
PDF size: 61.33 Kb.


Text Extraction

To the Editor
Non-alcoholic fatty liver disease (NAFLD) represents a clinical condition that may progress from steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. There are not enough information about the relationship between menopause and NAFLD, and this study evaluated the relevance of this liver disease in menopausal women (MPW), and the relationship between hormone replacement therapy (HTR) and NAFLD.


REFERENCES

  1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285:2486-97.

  2. Saito T, Misawa K, Kawata S. Fatty liver non-alcoholic steatohepatitis. Inter Med 2007; 46: 101-3.

  3. Cardoso CG Jr, Rosas FC, Oneda B, Labes E, Tinucci T, Abrahão SB, da Fonseca AM, et al. Aerobic training abolishes ambulatory blood pressure increase induced by estrogen therapy: A double blind randomized clinical trial. Maturitas 2011; 69: 189-94.

  4. Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402-9.

  5. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in chronic hepatitis C. Lancet 1997; 349: 825-32.

  6. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver ?brosis in hepatitis C virus infection: a cross-sectional and longitudinal study. Gut 2003; 52: 574-9.

  7. Codes L, Asselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormonereplacement therapy. Gut 2007; 56: 390-5.

  8. Villa E., Karampatou A., Cammà C, Alfredo di Leo, Luongo M, Ferrari A, Petta S, et al. Gastroenterology 2011; 140: 818-29.

  9. Corriveau P, Paquette A, Brochu M, Prud’homme D, et al. Resistance training prevents liver fat accumu lation in ovariectomized rats. Maturitas 2008; 59: 259-67.

  10. Kotoh K, Nakamuta M, Fukushima M, et al. Fertile females with nonalcoholic fatty liver disease (NAFLD) have higher levels of ALT thanpostmenopausal females: implications for the influence on NAFLD, Hepatogastroenterology 2007; 54: 224-28.

  11. Pfeilschifter J, Koditz F, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocrinol Rev 2002; 23: 90-119.

  12. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Kinetics of serum cytokines re?ect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002; 9: 134.




2020     |     www.medigraphic.com